SEATTLE, WA--(MARKET WIRE)--Aug 21, 2007 -- MitoPharm Corporation, Inc. (Other OTC:MTPM.PK - News), a biotechnology company, today announced that the United States Patent and Trademark Office has issued the company a notice of allowance for a patent based on a newly formulated compound, (-) Schisandrin B, that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology. A notice of allowance is a written notification that a patent application has cleared an internal review and is nearing issuance.
